ESC 365 - Antiplatelets and hemorrhagic MI outcome in reperfused STEMI

ESC2025 Premium Access

Antiplatelets and hemorrhagic MI outcome in reperfused STEMI

Session: Chronic coronary syndromes: antiplatelets

Topic: Pharmacotherapy

Speaker: Doctor K. Vora (Indianapolis, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Keyur Vora

Indiana University School of Medicine, Indianapolis (United States of America)

0 follower

5 more presentations in this session

Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation: insight from the OPTION trial

Speaker: Doctor L. Xu (Shanghai, CN)

Dual antiplatelet therapy de-escalation followed by aspirin or P2Y12 inhibitor monotherapy after PCI for acute coronary syndrome: a systematic review and meta-analysis

Speaker: Doctor C. Laudani (Catania, IT)

Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis

Speaker: Doctor R. Ibrahim (Phoenix, US)

The effect of ticagrelor on patients with acute myocardial infarction and malnutrition

Speaker: Professor K. Chen (Tianjin, CN)

Duration of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) for bifurcation lesions: insights from the ULTRA-BIFURCAT registry

Speaker: Doctor M. Nebiolo (Turin, IT)

Access the full session

Chronic coronary syndromes: antiplatelets

Speakers: Doctor K. Vora, Doctor L. Xu, Doctor C. Laudani, Doctor R. Ibrahim, Professor K. Chen...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources